Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer

The purpose of this study was to evaluate the prognostic ability of early changes of total prostate specific antigen (tPSA), free PSA (fPSA), [−2]proPSA and the Prostate Health Index (PHI) following initiation of Abiraterone-therapy in men with castration resistant prostate cancer (mCRPC). In 25 pat...

Full description

Bibliographic Details
Main Authors: Katrin Schlack, Laura-Maria Krabbe, Manfred Fobker, Andres Jan Schrader, Axel Semjonow, Martin Boegemann
Format: Article
Language:English
Published: MDPI AG 2016-09-01
Series:International Journal of Molecular Sciences
Subjects:
mCRPC
surrogate biomarker
abiraterone acetate
prognosticators
prostate cancer
[−2]proPSA
fPSA
PHI
tPSA
Online Access:http://www.mdpi.com/1422-0067/17/9/1520

Internet

http://www.mdpi.com/1422-0067/17/9/1520

Similar Items